

COVID-19 Information

[Public health information \(CDC\)](#)

[Research information \(NIH\)](#)

[SARS-CoV-2 data \(NCBI\)](#)

[Prevention and treatment information \(HHS\)](#)

[Español](#)



FULL TEXT LINKS

FULL TEXT article at
minervamedica.it

[Observational Study](#) > [Minerva Med.](#) 2018 Oct;109(5):358-362.

doi: 10.23736/S0026-4806.18.05710-5.

Observational clinical and nerve conduction study on effects of a nutraceutical combination on painful diabetic distal symmetric sensory-motor neuropathy in patients with diabetes type 1 and type 2

[Roberta Semprini](#)¹, [Alessandro Martorana](#)², [Mauro Ragonese](#)³, [Caterina Motta](#)²

Affiliations

PMID: 30338679 DOI: [10.23736/S0026-4806.18.05710-5](https://doi.org/10.23736/S0026-4806.18.05710-5)

Abstract

Background: Painful distal symmetric polyneuropathy (pDSPN) is one of the most common and invalidating complications of diabetes mellitus, both of type 1 and type 2. Mechanisms responsible for the occurrence of the pDSPN are multifactorial and involve metabolic pathways regulating inflammation, microvessel circulation, axonal degeneration and so on. Several therapeutic approaches have been proposed to treat pain and each of them showed positive effects associated to drug-related side effects.

Methods: Twenty-five consecutive patients with diagnosis of diabetes mellitus and pDSPN and tried to manage pain with a dietary supplement composed of a mixture of natural extracts (β -caryophyllene, myrrh, carnosic acid) and PEA. This is a nutraceutical with potential multiple effects on metabolic, pain and vascular compartments, a profile considered useful in pDSPN. Patients were enrolled and polyneuropathy evaluated by means of nerve conduction study. Pain was assessed using VAS score scale and MNSI. Each patient was evaluated at T0 (time of enrollment) and at T1 (after 16 weeks of treatment).

Results: Supplement administration was well tolerated and induced unexpectedly significant amelioration of polyneuropathy with increase amplitude and reduction of pain. No side effects were reported.

Conclusions: This fixed combination could well be considered as a potential nutraceutical option to manage pDSPN in diabetic patients.

Related information

[MedGen](#)

[PubChem Compound \(MeSH Keyword\)](#)

LinkOut - more resources

Full Text Sources

[Minerva Medica](#)

Medical

[Genetic Alliance](#)

[MedlinePlus Health Information](#)